Samar H. Ibrahim

Samar H. Ibrahim

Division of Gastroenterology & Hepatology, Mayo Clinic

Affiliated withMayo Clinic

Research Area

Biography

Dr. Ibrahim is the Principal Investigator of the NIH-funded lipotoxicity and liver inflammation laboratory at Mayo Clinic. She studies the mechanism of liver injury and inflammation in nonalcoholic steatohepatitis (NASH), with the goal to identify novel biomarkers and mechanism-based therapeutic targets. Her recently published work identified the vascular adhesion molecule 1 (VCAM1) as a potential novel therapeutic target in NASH. Dr. Ibrahim and her research team have examined the role of extracellular vesicles as biomarkers, as well as mediators of intercellular communication in NASH pathobiology. They recently defined the role of integrin β1-enriched extracellular vesicles in NASH. She is a member of the executive committee of the center of Cell Signaling in Gastroenterology at Mayo Clinic, and the director the Pilot and Feasibility program at the Digestive Disease Center at Mayo Clinic and moderates the center weekly Scientific Seminar Series. Dr. Ibrahim has served on NIDDK study sections, as well as a reviewer for international funding agencies. Dr. Ibrahim has mentored numerous medical students, residents, and postdoctoral fellows. She is an associate editor for “HEPATOLOGY” and a member of the basic science committee at the American Association for the study of Liver Diseases (AASLD) .

JoVE Journal Publications

ArticleTotal : 1
Year
Isolation and Characterization of Mouse Primary Liver Sinusoidal Endothelial Cells
Publication title

Cited by 6

2021

Other Publications

Article
Year
Incidence of gastrointestinal symptoms in children with autism: a population-based study.

Pediatrics| PubMed ID: 19651585

2009
2011
2011
Treatment of isolated gastric Crohn's disease with inhaled corticosteroids.

Case reports in gastroenterology| PubMed ID: 21490870

2008
Mechanisms of lipotoxicity in NAFLD and clinical implications.

Journal of pediatric gastroenterology and nutrition| PubMed ID: 21629127

2011
A 3-year-old with immunoglobulin G4-associated cholangitis.

Journal of pediatric gastroenterology and nutrition| PubMed ID: 21694546

2011
Who pulls the trigger: JNK activation in liver lipotoxicity?

Journal of hepatology| PubMed ID: 21703172

2012
2013
2013
2013
Mixed lineage kinase 3 deficient mice are protected against the high fat high carbohydrate diet-induced steatohepatitis.

Liver international : official journal of the International Association for the Study of the Liver| PubMed ID: 24256559

2014
2016
Animal Models of Nonalcoholic Steatohepatitis: Eat, Delete, and Inflame.

Digestive diseases and sciences| PubMed ID: 26626909

2016
2016
Omega-3 Fatty Acid-rich Parenteral Nutrition: Is It a Double-edged Sword?

Journal of pediatric gastroenterology and nutrition| PubMed ID: 27111227

2016
2016
2016
2016
2017
2017
2017
A Molecular Signature of Mouse NASH: A Step Closer to a Human Predictive Biomarker?

Cellular and molecular gastroenterology and hepatology| PubMed ID: 29276752

2018
2018
2018
2018
2019
2020
2021
Nonalcoholic Steatohepatitis Promoting Kinases.

Seminars in liver disease| PubMed ID: 32526787

2020
2020
2020
2020
2021
Sinusoidal endotheliopathy in nonalcoholic steatohepatitis: therapeutic implications.

American journal of physiology. Gastrointestinal and liver physiology| PubMed ID: 34037463

2021
2021
2021